Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Immunocore named Top Pick for first half of 2023 at BTIG » 09:01
01/03/23
01/03
09:01
01/03/23
09:01
ACET

Adicet Bio

$8.94 /

+0.41 (+4.81%)

, IMCR

Immunocore

$57.28 /

-0.64 (-1.10%)

BTIG analyst Justin Zelin…

BTIG analyst Justin Zelin names Immunocore (IMCR) as his BTIG Top Pick for first half of 2023, replacing Adicet Bio (ACET) on that list. The company has surprised observers of the field of TCR therapy with multiple corporate updates in 2022, led primarily by approval of lead asset KIMMTRAK, or tebentafusp, in January 2022 which was followed by strong revenue growth and distribution across international regions, the analyst tells investors in a research note. Zelin has a Buy rating and a $85 price target on the stock.

ShowHide Related Items >><<
IMCR Immunocore
$57.28 /

-0.64 (-1.10%)

ACET Adicet Bio
$8.94 /

+0.41 (+4.81%)

ACET Adicet Bio
$8.94 /

+0.41 (+4.81%)

12/12/22 H.C. Wainwright
Adicet Bio price target raised to $38 from $34 at H.C. Wainwright
09/21/22 JPMorgan
Adicet Bio initiated with Overweight, $23 target at JPMorgan
09/21/22 JPMorgan
Adicet Bio initiated with an Overweight at JPMorgan
03/30/22 SMBC Nikko
Adicet Bio initiated with an Outperform at SMBC Nikko
IMCR Immunocore
$57.28 /

-0.64 (-1.10%)

12/15/22 Goldman Sachs
Immunocore upgraded to Buy from Neutral at Goldman Sachs
11/30/22 Barclays
Immunocore initiated with an Overweight at Barclays
11/21/22 H.C. Wainwright
Immunocore price target raised to $90 from $80 at H.C. Wainwright
09/14/22 JPMorgan
Immunocore price target raised to $67 from $60 at JPMorgan
IMCR Immunocore
$57.28 /

-0.64 (-1.10%)

ACET Adicet Bio
$8.94 /

+0.41 (+4.81%)

ACET Adicet Bio
$8.94 /

+0.41 (+4.81%)

On The Fly
What You Missed On Wall Street On Monday » 16:25
12/12/22
12/12
16:25
12/12/22
16:25
AMGN

Amgen

$276.76 /

-1.825 (-0.66%)

, HZNP

Horizon Therapeutics

$112.34 /

+14.995 (+15.40%)

, COUP

Coupa Software

$78.62 /

+16.54 (+26.64%)

, WEBR

Weber

$8.01 /

+1.505 (+23.15%)

, RIVN

Rivian Automotive

$25.61 /

-1.68 (-6.16%)

, CVS

CVS Health

$103.78 /

+2.175 (+2.14%)

, WBA

Walgreens Boots Alliance

$41.06 /

+0.635 (+1.57%)

, MU

Micron

$55.36 /

+0.49 (+0.89%)

, UA

Under Armour

$9.12 /

+0.765 (+9.16%)

, UAA

Under Armour

$10.49 /

+0.96 (+10.07%)

, QCOM

Qualcomm

$121.20 /

+2.16 (+1.81%)

, ACN

Accenture

$292.32 /

+4.085 (+1.42%)

, GSP

Growth Fund of Spain

$20.27 /

+ (+0.00%)

, TPR

Tapestry

$37.34 /

+0.935 (+2.57%)

, RH

RH

$253.52 /

-20.82 (-7.59%)

, LEVI

Levi Strauss

$17.00 /

+0.605 (+3.69%)

, COIN

Coinbase

$42.60 /

+2.34 (+5.81%)

, SSNLF

Samsung

$40.60 /

+ (+0.00%)

, CS

Credit Suisse

$3.40 /

+0.025 (+0.74%)

, MSFT

Microsoft

$252.49 /

+7.12 (+2.90%)

, VMW

VMware

$122.61 /

+1.67 (+1.38%)

, PBI

Pitney Bowes

$4.30 /

+0.465 (+12.14%)

, BOX

Box

$30.22 /

+2.105 (+7.49%)

, ACET

Adicet Bio

$10.43 /

-6.84 (-39.62%)

, KPTI

Karyopharm

$3.86 /

-0.85 (-18.07%)

, FATE

Fate Therapeutics

$16.24 /

-2.65 (-14.03%)

, GTBP

GT Biopharma

$1.57 /

+ (+0.00%)

, FREE

Whole Earth Brands

$3.98 /

-0.27 (-6.36%)

, UTI

Universal Technical

$5.91 /

-1.24 (-17.34%)

, DLNG

Dynagas LNG

$2.73 /

-0.26 (-8.70%)

, PBA

Pembina Pipeline

$34.34 /

+0.765 (+2.28%)

, VIRC

Virco

$4.31 /

+0.3 (+7.48%)

Get caught up quickly on…

ShowHide Related Items >><<
WEBR Weber
$8.01 /

+1.505 (+23.15%)

WBA Walgreens Boots Alliance
$41.06 /

+0.635 (+1.57%)

VMW VMware
$122.61 /

+1.67 (+1.38%)

UTI Universal Technical
$5.91 /

-1.24 (-17.34%)

UA Under Armour
$9.12 /

+0.765 (+9.16%)

TPR Tapestry
$37.34 /

+0.935 (+2.57%)

SSNLF Samsung
$40.60 /

+ (+0.00%)

RIVN Rivian Automotive
$25.61 /

-1.68 (-6.16%)

RH RH
$253.52 /

-20.82 (-7.59%)

QCOM Qualcomm
$121.20 /

+2.16 (+1.81%)

PBI Pitney Bowes
$4.30 /

+0.465 (+12.14%)

PBA Pembina Pipeline
$34.34 /

+0.765 (+2.28%)

MU Micron
$55.36 /

+0.49 (+0.89%)

MSFT Microsoft
$252.49 /

+7.12 (+2.90%)

LEVI Levi Strauss
$17.00 /

+0.605 (+3.69%)

KPTI Karyopharm
$3.86 /

-0.85 (-18.07%)

HZNP Horizon Therapeutics
$112.34 /

+14.995 (+15.40%)

GTBP GT Biopharma
$1.57 /

+ (+0.00%)

FREE Whole Earth Brands
$3.98 /

-0.27 (-6.36%)

FATE Fate Therapeutics
$16.24 /

-2.65 (-14.03%)

DLNG Dynagas LNG
$2.73 /

-0.26 (-8.70%)

CVS CVS Health
$103.78 /

+2.175 (+2.14%)

CS Credit Suisse
$3.40 /

+0.025 (+0.74%)

COUP Coupa Software
$78.62 /

+16.54 (+26.64%)

COIN Coinbase
$42.60 /

+2.34 (+5.81%)

BOX Box
$30.22 /

+2.105 (+7.49%)

AMGN Amgen
$276.76 /

-1.825 (-0.66%)

ACN Accenture
$292.32 /

+4.085 (+1.42%)

ACET Adicet Bio
$10.43 /

-6.84 (-39.62%)

AMGN Amgen
$276.76 /

-1.825 (-0.66%)

12/13/22 BMO Capital
Horizon Therapeutics downgraded to Market Perform from Outperform at BMO Capital
12/13/22 Baird
Amgen deal yields nice accretion but large debt position, says Baird
12/13/22 Wells Fargo
Horizon Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
12/13/22 Guggenheim
Horizon Therapeutics downgraded to Neutral from Buy at Guggenheim
HZNP Horizon Therapeutics
$112.34 /

+14.995 (+15.40%)

COUP Coupa Software
$78.62 /

+16.54 (+26.64%)

12/13/22 Needham
Coupa Software downgraded to Hold from Buy at Needham
12/13/22 Wells Fargo
Coupa Software price target raised to $81 from $65 at Wells Fargo
12/13/22 Needham
Coupa Software downgraded to Hold from Buy at Needham
12/13/22 Wolfe Research
Coupa Software downgraded to Peer Perform from Outperform at Wolfe Research
WEBR Weber
$8.01 /

+1.505 (+23.15%)

12/12/22 Credit Suisse
Credit Suisse views Weber go-private deal 'positively'
10/25/22 Wells Fargo
Weber upgraded to Equal Weight from Underweight at Wells Fargo
08/17/22 Citi
Weber downgraded to Sell from Neutral at Citi
08/16/22 BMO Capital
Weber price target lowered to $6 from $7 at BMO Capital
RIVN Rivian Automotive
$25.61 /

-1.68 (-6.16%)

12/13/22 Canaccord
Rivian Automotive production pause preserves capital, says Canaccord
12/13/22 Baird
Rivian Automotive price target lowered to $44 from $51 at Baird
11/29/22 Evercore ISI
Rivian Automotive initiated with an In Line, $35 target at Evercore ISI
11/29/22 Evercore ISI
Rivian Automotive initiated with an In Line at Evercore ISI
CVS CVS Health
$103.78 /

+2.175 (+2.14%)

11/23/22 Morgan Stanley
CVS Health assumed with an Overweight at Morgan Stanley
11/21/22 Credit Suisse
CVS Health price target raised to $125 from $117 at Credit Suisse
11/06/22 Raymond James
CVS Health price target lowered to $115 from $120 at Raymond James
11/02/22 B. Riley
B. Riley downgrades Semler Scientific on risk from Signify buyout
WBA Walgreens Boots Alliance
$41.06 /

+0.635 (+1.57%)

11/23/22 Morgan Stanley
Walgreens Boots Alliance assumed with an Underweight at Morgan Stanley
11/22/22 Cowen
Walgreens upgraded to Outperform on services transition at Cowen
11/22/22 Cowen
Walgreens Boots Alliance upgraded to Outperform from Market Perform at Cowen
11/18/22 JPMorgan
Walgreens Boots Alliance upgraded to Overweight from Neutral at JPMorgan
MU Micron
$55.36 /

+0.49 (+0.89%)

12/12/22 Deutsche Bank
Micron downgraded to Hold from Buy at Deutsche Bank
12/07/22 Wells Fargo
Micron price target lowered to $70 from $75 at Wells Fargo
12/05/22 Lynx
Micron price target raised to $60 from $56 at Lynx
11/30/22 Stifel
Micron management's tone 'incrementally downbeat,' says Stifel
UA Under Armour
$9.12 /

+0.765 (+9.16%)

12/12/22 Stifel
Under Armour upgraded to Buy from Hold at Stifel
11/07/22 JPMorgan
Under Armour price target raised to $11 from $10 at JPMorgan
11/01/22 BofA
Under Armour reinstated with a Neutral at BofA
10/31/22 JPMorgan
Under Armour price target lowered to $10 from $12 at JPMorgan
UAA Under Armour
$10.49 /

+0.96 (+10.07%)

QCOM Qualcomm
$121.20 /

+2.16 (+1.81%)

12/12/22 Wells Fargo
Wells Fargo downgrades Qualcomm to Underweight with $105 price target
12/12/22 Wells Fargo
Qualcomm downgraded to Underweight from Equal Weight at Wells Fargo
11/15/22 Credit Suisse
Qualcomm initiated with an Outperform at Credit Suisse
11/03/22 KeyBanc
Qualcomm price target lowered to $150 from $170 at KeyBanc
ACN Accenture
$292.32 /

+4.085 (+1.42%)

12/12/22 Piper Sandler
Accenture downgraded to Underweight from Neutral at Piper Sandler
10/14/22 JPMorgan
Accenture price target lowered to $306 from $329 at JPMorgan
10/13/22 Wells Fargo
Wells sees some encouraging signs from emerging metaverse app economy
09/27/22 Alliance Global Partners
Perficient upgraded to Buy from Neutral at Alliance Global Partners
GSP Growth Fund of Spain
$20.27 /

+ (+0.00%)

TPR Tapestry
$37.34 /

+0.935 (+2.57%)

12/13/22 Morgan Stanley
Nike price target raised to $127 from $120 at Morgan Stanley
12/12/22 Goldman Sachs
Tapestry upgraded to Buy from Neutral at Goldman Sachs
11/29/22 JPMorgan
Tapestry price target raised to $47 from $46 at JPMorgan
11/14/22 Citi
Tapestry price target lowered to $40 from $42 at Citi
RH RH
$253.52 /

-20.82 (-7.59%)

12/13/22 Needham
Williams-Sonoma initiated with a Hold at Needham
12/12/22 Cowen
RH price target lowered to $320 from $350 at Cowen
12/12/22 Loop Capital
RH price target lowered to $370 from $420 at Loop Capital
12/12/22 Barclays
RH price target raised to $254 from $243 at Barclays
LEVI Levi Strauss
$17.00 /

+0.605 (+3.69%)

12/12/22 Goldman Sachs
Levi Strauss downgraded to Neutral from Buy at Goldman Sachs
11/29/22 JPMorgan
Levi Strauss price target lowered to $19 from $20 at JPMorgan
10/10/22 Citi
Levi Strauss price target lowered to $19 from $27 at Citi
10/07/22 Guggenheim
Levi Strauss price target lowered to $27 from $33 at Guggenheim
COIN Coinbase
$42.60 /

+2.34 (+5.81%)

12/12/22 KeyBanc
Coinbase initiated with a Sector Weight at KeyBanc
12/12/22 Mizuho
Fiserv price target lowered to $135 from $145 at Mizuho
12/09/22 Mizuho
Coinbase downgraded to Underperform from Neutral at Mizuho
12/05/22 Atlantic Equities
Coinbase price target lowered to $46 from $67 at Atlantic Equities
SSNLF Samsung
$40.60 /

+ (+0.00%)

11/25/22 William Blair
Report about Galaxy S23 'significant positive' for Iridium, says William Blair
08/22/22 Loop Capital
Enovix price target raised to $100 from $50 at Loop Capital
08/11/22 Loop Capital
Loop Capital has 'stronger conviction' in Enovix after 'customer milestones'
06/22/22 Loop Capital
Samsung initiated with a Buy at Loop Capital
CS Credit Suisse
$3.40 /

+0.025 (+0.74%)

12/09/22 BofA
BofA upgrades Credit Suisse to Buy, sees more than 20% upside potential
12/09/22 BofA
Credit Suisse upgraded to Buy from Neutral at BofA
12/01/22 JPMorgan
Credit Suisse price target lowered to CHF 3.80 from CHF 5.50 at JPMorgan
11/07/22 AlphaValue/Baader
Credit Suisse downgraded to Sell from Buy at AlphaValue/Baader
MSFT Microsoft
$252.49 /

+7.12 (+2.90%)

12/08/22 Citi
DoD contracts shows competitiveness of cloud industry, says Citi
12/07/22 BTIG
SentinelOne price target lowered to $20 from $25 at BTIG
12/01/22 BMO Capital
Okta price target raised to $69 from $58 at BMO Capital
12/01/22 Wedbush
Activision Blizzard added to Best Ideas List at Wedbush
VMW VMware
$122.61 /

+1.67 (+1.38%)

11/15/22 Mizuho
VMware price target lowered to $135 from $138 at Mizuho
10/17/22 Needham
Nutanix price target raised to $31 from $25 at Needham
10/17/22 Northland
Salesforce initiated with a Market Perform at Northland
07/06/22 Raymond James
VMware downgraded to Market Perform from Outperform at Raymond James
PBI Pitney Bowes
$4.30 /

+0.465 (+12.14%)

02/02/22 Maxim
Pitney Bowes price target lowered to $7 from $12 at Maxim
BOX Box
$30.22 /

+2.105 (+7.49%)

12/12/22 RBC Capital
Coupa Software upgraded to Sector Perform from Underperform at RBC Capital
12/12/22 JPMorgan
JPMorgan upgrades 'undervalued profitable growth story' Box to buy
12/12/22 JPMorgan
Box upgraded to Overweight from Neutral at JPMorgan
11/21/22 Credit Suisse
Box initiated with an Outperform at Credit Suisse
ACET Adicet Bio
$10.43 /

-6.84 (-39.62%)

12/12/22 H.C. Wainwright
Adicet Bio price target raised to $38 from $34 at H.C. Wainwright
09/21/22 JPMorgan
Adicet Bio initiated with Overweight, $23 target at JPMorgan
09/21/22 JPMorgan
Adicet Bio initiated with an Overweight at JPMorgan
03/30/22 SMBC Nikko
Adicet Bio initiated with an Outperform at SMBC Nikko
KPTI Karyopharm
$3.86 /

-0.85 (-18.07%)

11/04/22 RBC Capital
Karyopharm upgraded to Outperform from Sector Perform at RBC Capital
11/04/22 RBC Capital
Karyopharm upgraded to Outperform from Sector Perform at RBC Capital
08/05/22 Baird
Karyopharm price target lowered to $14 from $17 at Baird
08/05/22 Barclays
Karyopharm price target lowered to $8 from $14 at Barclays
FATE Fate Therapeutics
$16.24 /

-2.65 (-14.03%)

12/12/22 Oppenheimer
Fate Therapeutics price target lowered to $65 from $90 at Oppenheimer
11/16/22 Citi
Fate Therapeutics price target lowered to $80 from $87 at Citi
11/04/22 Cantor Fitzgerald
Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/10/22 Canaccord
Fate Therapeutics initiated with a Buy at Canaccord
GTBP GT Biopharma
$1.57 /

+ (+0.00%)

09/13/22 H.C. Wainwright
GT Biopharma price target lowered to $5 from $25 at H.C. Wainwright
08/11/22 Roth MKM
Roth cuts GT Biopharma to Neutral after filings for TriKE programs pushed back
08/11/22 Roth MKM
GT Biopharma downgraded to Neutral from Buy at Roth Capital
01/24/22 B. Riley
GT Biopharma price target lowered to $18 from $26 at B. Riley
FREE Whole Earth Brands
$3.98 /

-0.27 (-6.36%)

11/21/22 Cowen
Whole Earth Brands price target lowered to $11 from $14 at Cowen
11/10/22 Canaccord
Whole Earth Brands price target lowered to $8 from $10 at Canaccord
03/15/22 Lake Street
Whole Earth Brands price target lowered to $16 from $19 at Lake Street
03/15/22 Cantor Fitzgerald
Whole Earth Brands price target lowered to $19.00 from $24.75 at Cantor Fitzgerald
UTI Universal Technical
$5.91 /

-1.24 (-17.34%)

07/11/22 Rosenblatt
Universal Technical initiated with a Buy at Rosenblatt
06/28/22 Argus
Argus upgrades Universal Technical to Buy on expansion efforts, valuation
06/28/22 Argus
Universal Technical upgraded to Buy from Hold at Argus
05/05/22 Barrington
Universal Technical price target raised to $14 from $10 at Barrington
DLNG Dynagas LNG
$2.73 /

-0.26 (-8.70%)

04/27/22 Jefferies
Dynagas LNG reinstated with a Hold at Jefferies
PBA Pembina Pipeline
$34.34 /

+0.765 (+2.28%)

12/09/22 Credit Suisse
Pembina Pipeline downgraded to Neutral from Outperform at Credit Suisse
11/07/22 National Bank
Pembina Pipeline price target raised to C$46 from C$45 at National Bank
11/04/22 Raymond James
Pembina Pipeline price target lowered to C$46 from C$49 at Raymond James
10/20/22 Scotiabank
Pembina Pipeline price target lowered to C$50 from C$55 at Scotiabank
VIRC Virco
$4.31 /

+0.3 (+7.48%)

WEBR Weber
$8.01 /

+1.505 (+23.15%)

WBA Walgreens Boots Alliance
$41.06 /

+0.635 (+1.57%)

VMW VMware
$122.61 /

+1.67 (+1.38%)

VIRC Virco
$4.31 /

+0.3 (+7.48%)

UTI Universal Technical
$5.91 /

-1.24 (-17.34%)

UA Under Armour
$9.12 /

+0.765 (+9.16%)

TPR Tapestry
$37.34 /

+0.935 (+2.57%)

SSNLF Samsung
$40.60 /

+ (+0.00%)

RIVN Rivian Automotive
$25.61 /

-1.68 (-6.16%)

RH RH
$253.52 /

-20.82 (-7.59%)

QCOM Qualcomm
$121.20 /

+2.16 (+1.81%)

PBI Pitney Bowes
$4.30 /

+0.465 (+12.14%)

PBA Pembina Pipeline
$34.34 /

+0.765 (+2.28%)

MU Micron
$55.36 /

+0.49 (+0.89%)

MSFT Microsoft
$252.49 /

+7.12 (+2.90%)

LEVI Levi Strauss
$17.00 /

+0.605 (+3.69%)

KPTI Karyopharm
$3.86 /

-0.85 (-18.07%)

HZNP Horizon Therapeutics
$112.34 /

+14.995 (+15.40%)

FREE Whole Earth Brands
$3.98 /

-0.27 (-6.36%)

FATE Fate Therapeutics
$16.24 /

-2.65 (-14.03%)

DLNG Dynagas LNG
$2.73 /

-0.26 (-8.70%)

CVS CVS Health
$103.78 /

+2.175 (+2.14%)

CS Credit Suisse
$3.40 /

+0.025 (+0.74%)

COUP Coupa Software
$78.62 /

+16.54 (+26.64%)

COIN Coinbase
$42.60 /

+2.34 (+5.81%)

BOX Box
$30.22 /

+2.105 (+7.49%)

AMGN Amgen
$276.76 /

-1.825 (-0.66%)

ACN Accenture
$292.32 /

+4.085 (+1.42%)

ACET Adicet Bio
$10.43 /

-6.84 (-39.62%)

WEBR Weber
$8.01 /

+1.505 (+23.15%)

WBA Walgreens Boots Alliance
$41.06 /

+0.635 (+1.57%)

VMW VMware
$122.61 /

+1.67 (+1.38%)

UA Under Armour
$9.12 /

+0.765 (+9.16%)

TPR Tapestry
$37.34 /

+0.935 (+2.57%)

SSNLF Samsung
$40.60 /

+ (+0.00%)

RIVN Rivian Automotive
$25.61 /

-1.68 (-6.16%)

QCOM Qualcomm
$121.20 /

+2.16 (+1.81%)

MU Micron
$55.36 /

+0.49 (+0.89%)

MSFT Microsoft
$252.49 /

+7.12 (+2.90%)

HZNP Horizon Therapeutics
$112.34 /

+14.995 (+15.40%)

DLNG Dynagas LNG
$2.73 /

-0.26 (-8.70%)

CVS CVS Health
$103.78 /

+2.175 (+2.14%)

CS Credit Suisse
$3.40 /

+0.025 (+0.74%)

COUP Coupa Software
$78.62 /

+16.54 (+26.64%)

COIN Coinbase
$42.60 /

+2.34 (+5.81%)

AMGN Amgen
$276.76 /

-1.825 (-0.66%)

ACN Accenture
$292.32 /

+4.085 (+1.42%)

WEBR Weber
$8.01 /

+1.505 (+23.15%)

WBA Walgreens Boots Alliance
$41.06 /

+0.635 (+1.57%)

VMW VMware
$122.61 /

+1.67 (+1.38%)

UTI Universal Technical
$5.91 /

-1.24 (-17.34%)

TPR Tapestry
$37.34 /

+0.935 (+2.57%)

SSNLF Samsung
$40.60 /

+ (+0.00%)

RIVN Rivian Automotive
$25.61 /

-1.68 (-6.16%)

RH RH
$253.52 /

-20.82 (-7.59%)

MU Micron
$55.36 /

+0.49 (+0.89%)

MSFT Microsoft
$252.49 /

+7.12 (+2.90%)

LEVI Levi Strauss
$17.00 /

+0.605 (+3.69%)

HZNP Horizon Therapeutics
$112.34 /

+14.995 (+15.40%)

FATE Fate Therapeutics
$16.24 /

-2.65 (-14.03%)

DLNG Dynagas LNG
$2.73 /

-0.26 (-8.70%)

CVS CVS Health
$103.78 /

+2.175 (+2.14%)

CS Credit Suisse
$3.40 /

+0.025 (+0.74%)

COUP Coupa Software
$78.62 /

+16.54 (+26.64%)

COIN Coinbase
$42.60 /

+2.34 (+5.81%)

BOX Box
$30.22 /

+2.105 (+7.49%)

AMGN Amgen
$276.76 /

-1.825 (-0.66%)

ACN Accenture
$292.32 /

+4.085 (+1.42%)

WEBR Weber
$8.01 /

+1.505 (+23.15%)

WBA Walgreens Boots Alliance
$41.06 /

+0.635 (+1.57%)

VMW VMware
$122.61 /

+1.67 (+1.38%)

UAA Under Armour
$10.49 /

+0.96 (+10.07%)

TPR Tapestry
$37.34 /

+0.935 (+2.57%)

RIVN Rivian Automotive
$25.61 /

-1.68 (-6.16%)

RH RH
$253.52 /

-20.82 (-7.59%)

QCOM Qualcomm
$121.20 /

+2.16 (+1.81%)

MU Micron
$55.36 /

+0.49 (+0.89%)

MSFT Microsoft
$252.49 /

+7.12 (+2.90%)

LEVI Levi Strauss
$17.00 /

+0.605 (+3.69%)

HZNP Horizon Therapeutics
$112.34 /

+14.995 (+15.40%)

CVS CVS Health
$103.78 /

+2.175 (+2.14%)

CS Credit Suisse
$3.40 /

+0.025 (+0.74%)

COUP Coupa Software
$78.62 /

+16.54 (+26.64%)

COIN Coinbase
$42.60 /

+2.34 (+5.81%)

BOX Box
$30.22 /

+2.105 (+7.49%)

AMGN Amgen
$276.76 /

-1.825 (-0.66%)

On The Fly
What You Missed On Wall Street This Morning » 12:17
12/12/22
12/12
12:17
12/12/22
12:17
AMGN

Amgen

$275.13 /

-3.455 (-1.24%)

, HZNP

Horizon Therapeutics

$112.03 /

+14.68 (+15.08%)

, COUP

Coupa Software

$78.70 /

+16.62 (+26.77%)

, WEBR

Weber

$8.03 /

+1.525 (+23.46%)

, RIVN

Rivian Automotive

$26.25 /

-1.04 (-3.81%)

, NOTV

Inotiv

$4.26 /

-1.44 (-25.26%)

, COIN

Coinbase

$41.81 /

+1.55 (+3.85%)

, SSNLF

Samsung

$40.60 /

+ (+0.00%)

, CS

Credit Suisse

$3.36 /

-0.02 (-0.59%)

, MSFT

Microsoft

$250.15 /

+4.78 (+1.95%)

, ATVI

Activision Blizzard

$75.33 /

+0.165 (+0.22%)

, IAC

IAC

$45.95 /

-0.11 (-0.24%)

, VIVO

Meridian Bioscience

$33.57 /

+2.38 (+7.63%)

, BOX

Box

$29.93 /

+1.815 (+6.46%)

, ACET

Adicet Bio

$10.60 /

-6.67 (-38.63%)

, KPTI

Karyopharm

$4.00 /

-0.71 (-15.09%)

, FATE

Fate Therapeutics

$16.45 /

-2.44 (-12.92%)

, GTBP

GT Biopharma

$1.74 /

+0.175 (+11.18%)

, FREE

Whole Earth Brands

$4.14 /

-0.105 (-2.47%)

, UTI

Universal Technical

$5.98 /

-1.17 (-16.36%)

, DLNG

Dynagas LNG

$2.80 /

-0.19 (-6.35%)

, PBA

Pembina Pipeline

$34.05 /

+0.48 (+1.43%)

, VIRC

Virco

$4.22 /

+0.21 (+5.24%)

, MU

Micron

$54.12 /

-0.75 (-1.37%)

, RH

RH

$252.26 /

-22.08 (-8.05%)

, UAA

Under Armour

$10.44 /

+0.91 (+9.55%)

, QCOM

Qualcomm

$119.66 /

+0.62 (+0.52%)

, ACN

Accenture

$290.81 /

+2.58 (+0.90%)

, GPS

Gap

$13.95 /

+0.04 (+0.29%)

, TPR

Tapestry

$36.75 /

+0.345 (+0.95%)

, LEVI

Levi Strauss

$16.65 /

+0.26 (+1.59%)

, UA

Under Armour

$9.09 /

+0.735 (+8.80%)

Get caught up quickly on…

ShowHide Related Items >><<
WEBR Weber
$8.03 /

+1.525 (+23.46%)

VIVO Meridian Bioscience
$33.57 /

+2.38 (+7.63%)

UTI Universal Technical
$5.98 /

-1.17 (-16.36%)

UAA Under Armour
$10.44 /

+0.91 (+9.55%)

TPR Tapestry
$36.75 /

+0.345 (+0.95%)

SSNLF Samsung
$40.60 /

+ (+0.00%)

RIVN Rivian Automotive
$26.25 /

-1.04 (-3.81%)

RH RH
$252.26 /

-22.08 (-8.05%)

QCOM Qualcomm
$119.66 /

+0.62 (+0.52%)

PBA Pembina Pipeline
$34.05 /

+0.48 (+1.43%)

NOTV Inotiv
$4.26 /

-1.44 (-25.26%)

MU Micron
$54.12 /

-0.75 (-1.37%)

MSFT Microsoft
$250.15 /

+4.78 (+1.95%)

LEVI Levi Strauss
$16.65 /

+0.26 (+1.59%)

KPTI Karyopharm
$4.00 /

-0.71 (-15.09%)

IAC IAC
$45.95 /

-0.11 (-0.24%)

HZNP Horizon Therapeutics
$112.03 /

+14.68 (+15.08%)

GTBP GT Biopharma
$1.74 /

+0.175 (+11.18%)

GPS Gap
$13.95 /

+0.04 (+0.29%)

FREE Whole Earth Brands
$4.14 /

-0.105 (-2.47%)

FATE Fate Therapeutics
$16.45 /

-2.44 (-12.92%)

DLNG Dynagas LNG
$2.80 /

-0.19 (-6.35%)

CS Credit Suisse
$3.36 /

-0.02 (-0.59%)

COUP Coupa Software
$78.70 /

+16.62 (+26.77%)

COIN Coinbase
$41.81 /

+1.55 (+3.85%)

BOX Box
$29.93 /

+1.815 (+6.46%)

ATVI Activision Blizzard
$75.33 /

+0.165 (+0.22%)

AMGN Amgen
$275.13 /

-3.455 (-1.24%)

ACN Accenture
$290.81 /

+2.58 (+0.90%)

ACET Adicet Bio
$10.60 /

-6.67 (-38.63%)

AMGN Amgen
$275.13 /

-3.455 (-1.24%)

12/12/22 Stifel
Horizon Therapeutics downgraded to Hold from Buy at Stifel
12/07/22 Piper Sandler
Horizon Therapeutics price target raised to $110 from $90 at Piper Sandler
12/06/22 Oppenheimer
Amgen price target raised to $310 from $300 at Oppenheimer
12/05/22 Piper Sandler
Amgen price target raised to $297 from $278 at Piper Sandler
HZNP Horizon Therapeutics
$112.03 /

+14.68 (+15.08%)

12/01/22 Jefferies
Horizon Therapeutics price target raised to $125 from $101 at Jefferies
11/30/22 Cowen
Horizon Therapeutics takeout in $120-$140 range reasonable, says Cowen
COUP Coupa Software
$78.70 /

+16.62 (+26.77%)

12/12/22 William Blair
Coupa Software downgraded to Market Perform from Outperform at William Blair
11/25/22 Raymond James
Coupa Software takeout would be 'reasonable' at $68-$80, say Raymond James
11/25/22 Truist
Truist sees 'scarcity value' in Coupa platform, keeps $75 target
11/25/22 BofA
Coupa has strategic value, could also represent attractive PE target, says BofA
WEBR Weber
$8.03 /

+1.525 (+23.46%)

10/25/22 Wells Fargo
Weber upgraded to Equal Weight from Underweight at Wells Fargo
08/17/22 Citi
Weber downgraded to Sell from Neutral at Citi
08/16/22 BMO Capital
Weber price target lowered to $6 from $7 at BMO Capital
08/02/22 Citi
Weber transferred with Neutral rating at Citi
RIVN Rivian Automotive
$26.25 /

-1.04 (-3.81%)

11/29/22 Evercore ISI
Rivian Automotive initiated with an In Line, $35 target at Evercore ISI
11/29/22 Evercore ISI
Rivian Automotive initiated with an In Line at Evercore ISI
11/10/22 RBC Capital
Rivian Automotive price target lowered to $50 from $61 at RBC Capital
11/10/22 Deutsche Bank
Rivian Automotive price target lowered to $43 from $44 at Deutsche Bank
NOTV Inotiv
$4.26 /

-1.44 (-25.26%)

11/18/22 Lake Street
Inotiv downgraded to Hold from Buy at Lake Street
10/04/22 Jefferies
Inotiv initiated with a Buy at Jefferies
08/11/22 Lake Street
Inotiv price target raised to $60 from $50 at Lake Street
06/14/22 Lake Street
Inotiv price target lowered to $50 from $75 at Lake Street
COIN Coinbase
$41.81 /

+1.55 (+3.85%)

12/12/22 KeyBanc
Coinbase initiated with a Sector Weight at KeyBanc
12/12/22 Mizuho
Fiserv price target lowered to $135 from $145 at Mizuho
12/09/22 Mizuho
Coinbase downgraded to Underperform from Neutral at Mizuho
12/05/22 Atlantic Equities
Coinbase price target lowered to $46 from $67 at Atlantic Equities
SSNLF Samsung
$40.60 /

+ (+0.00%)

11/25/22 William Blair
Report about Galaxy S23 'significant positive' for Iridium, says William Blair
08/22/22 Loop Capital
Enovix price target raised to $100 from $50 at Loop Capital
08/11/22 Loop Capital
Loop Capital has 'stronger conviction' in Enovix after 'customer milestones'
06/22/22 Loop Capital
Samsung initiated with a Buy at Loop Capital
CS Credit Suisse
$3.36 /

-0.02 (-0.59%)

12/09/22 BofA
BofA upgrades Credit Suisse to Buy, sees more than 20% upside potential
12/09/22 BofA
Credit Suisse upgraded to Buy from Neutral at BofA
12/01/22 JPMorgan
Credit Suisse price target lowered to CHF 3.80 from CHF 5.50 at JPMorgan
11/07/22 AlphaValue/Baader
Credit Suisse downgraded to Sell from Buy at AlphaValue/Baader
MSFT Microsoft
$250.15 /

+4.78 (+1.95%)

12/08/22 Citi
DoD contracts shows competitiveness of cloud industry, says Citi
12/07/22 BTIG
SentinelOne price target lowered to $20 from $25 at BTIG
12/01/22 BMO Capital
Okta price target raised to $69 from $58 at BMO Capital
12/01/22 Wedbush
Activision Blizzard added to Best Ideas List at Wedbush
ATVI Activision Blizzard
$75.33 /

+0.165 (+0.22%)

12/06/22 Edward Jones
Activision Blizzard upgraded to Buy from Hold at Edward Jones
11/28/22 JPMorgan
Activision Blizzard price target lowered to $86 from $95 at JPMorgan
11/28/22 Wells Fargo
Wells Fargo upgrades Activision Blizzard to Overweight with $95 price target
IAC IAC
$45.95 /

-0.11 (-0.24%)

12/02/22 UBS
IAC initiated with a Sell at UBS
11/14/22 Wells Fargo
IAC price target lowered to $85 from $120 at Wells Fargo
11/10/22 Cowen
IAC price target lowered to $75 from $80 at Cowen
11/10/22 Truist
IACprice target lowered to $120 from $155 at Truist
VIVO Meridian Bioscience
$33.57 /

+2.38 (+7.63%)

07/08/22 H.C. Wainwright
Meridian Bioscience downgraded to Neutral from Buy at H.C. Wainwright
07/07/22 William Blair
Meridian Bioscience downgraded to Market Perform from Outperform at William Blair
02/07/22 H.C. Wainwright
Meridian Bioscience price target raised to $30 from $28 at H.C. Wainwright
BOX Box
$29.93 /

+1.815 (+6.46%)

12/12/22 JPMorgan
JPMorgan upgrades 'undervalued profitable growth story' Box to buy
12/12/22 JPMorgan
Box upgraded to Overweight from Neutral at JPMorgan
11/21/22 Credit Suisse
Box initiated with an Outperform at Credit Suisse
10/03/22 Morgan Stanley
Morgan Stanley upgrades Box on 'strong large deal momentum'
ACET Adicet Bio
$10.60 /

-6.67 (-38.63%)

12/12/22 H.C. Wainwright
Adicet Bio price target raised to $38 from $34 at H.C. Wainwright
09/21/22 JPMorgan
Adicet Bio initiated with Overweight, $23 target at JPMorgan
09/21/22 JPMorgan
Adicet Bio initiated with an Overweight at JPMorgan
03/30/22 SMBC Nikko
Adicet Bio initiated with an Outperform at SMBC Nikko
KPTI Karyopharm
$4.00 /

-0.71 (-15.09%)

11/04/22 RBC Capital
Karyopharm upgraded to Outperform from Sector Perform at RBC Capital
11/04/22 RBC Capital
Karyopharm upgraded to Outperform from Sector Perform at RBC Capital
08/05/22 Baird
Karyopharm price target lowered to $14 from $17 at Baird
08/05/22 Barclays
Karyopharm price target lowered to $8 from $14 at Barclays
FATE Fate Therapeutics
$16.45 /

-2.44 (-12.92%)

12/12/22 Oppenheimer
Fate Therapeutics price target lowered to $65 from $90 at Oppenheimer
11/16/22 Citi
Fate Therapeutics price target lowered to $80 from $87 at Citi
11/04/22 Cantor Fitzgerald
Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/10/22 Canaccord
Fate Therapeutics initiated with a Buy at Canaccord
GTBP GT Biopharma
$1.74 /

+0.175 (+11.18%)

09/13/22 H.C. Wainwright
GT Biopharma price target lowered to $5 from $25 at H.C. Wainwright
08/11/22 Roth MKM
Roth cuts GT Biopharma to Neutral after filings for TriKE programs pushed back
08/11/22 Roth MKM
GT Biopharma downgraded to Neutral from Buy at Roth Capital
01/24/22 B. Riley
GT Biopharma price target lowered to $18 from $26 at B. Riley
FREE Whole Earth Brands
$4.14 /

-0.105 (-2.47%)

11/21/22 Cowen
Whole Earth Brands price target lowered to $11 from $14 at Cowen
11/10/22 Canaccord
Whole Earth Brands price target lowered to $8 from $10 at Canaccord
03/15/22 Lake Street
Whole Earth Brands price target lowered to $16 from $19 at Lake Street
03/15/22 Cantor Fitzgerald
Whole Earth Brands price target lowered to $19.00 from $24.75 at Cantor Fitzgerald
UTI Universal Technical
$5.98 /

-1.17 (-16.36%)

07/11/22 Rosenblatt
Universal Technical initiated with a Buy at Rosenblatt
06/28/22 Argus
Argus upgrades Universal Technical to Buy on expansion efforts, valuation
06/28/22 Argus
Universal Technical upgraded to Buy from Hold at Argus
05/05/22 Barrington
Universal Technical price target raised to $14 from $10 at Barrington
DLNG Dynagas LNG
$2.80 /

-0.19 (-6.35%)

04/27/22 Jefferies
Dynagas LNG reinstated with a Hold at Jefferies
PBA Pembina Pipeline
$34.05 /

+0.48 (+1.43%)

12/09/22 Credit Suisse
Pembina Pipeline downgraded to Neutral from Outperform at Credit Suisse
11/07/22 National Bank
Pembina Pipeline price target raised to C$46 from C$45 at National Bank
11/04/22 Raymond James
Pembina Pipeline price target lowered to C$46 from C$49 at Raymond James
10/20/22 Scotiabank
Pembina Pipeline price target lowered to C$50 from C$55 at Scotiabank
VIRC Virco
$4.22 /

+0.21 (+5.24%)

MU Micron
$54.12 /

-0.75 (-1.37%)

12/12/22 Deutsche Bank
Micron downgraded to Hold from Buy at Deutsche Bank
12/07/22 Wells Fargo
Micron price target lowered to $70 from $75 at Wells Fargo
12/05/22 Lynx
Micron price target raised to $60 from $56 at Lynx
11/30/22 Stifel
Micron management's tone 'incrementally downbeat,' says Stifel
RH RH
$252.26 /

-22.08 (-8.05%)

12/12/22 Cowen
RH price target lowered to $320 from $350 at Cowen
12/12/22 Loop Capital
RH price target lowered to $370 from $420 at Loop Capital
12/12/22 Barclays
RH price target raised to $254 from $243 at Barclays
12/12/22 Goldman Sachs
RH downgraded to Sell from Neutral at Goldman Sachs
UAA Under Armour
$10.44 /

+0.91 (+9.55%)

12/12/22 Stifel
Under Armour upgraded to Buy from Hold at Stifel
11/07/22 JPMorgan
Under Armour price target raised to $11 from $10 at JPMorgan
11/01/22 BofA
Under Armour reinstated with a Neutral at BofA
10/31/22 JPMorgan
Under Armour price target lowered to $10 from $12 at JPMorgan
QCOM Qualcomm
$119.66 /

+0.62 (+0.52%)

12/12/22 Wells Fargo
Wells Fargo downgrades Qualcomm to Underweight with $105 price target
12/12/22 Wells Fargo
Qualcomm downgraded to Underweight from Equal Weight at Wells Fargo
11/15/22 Credit Suisse
Qualcomm initiated with an Outperform at Credit Suisse
11/03/22 KeyBanc
Qualcomm price target lowered to $150 from $170 at KeyBanc
ACN Accenture
$290.81 /

+2.58 (+0.90%)

12/12/22 Piper Sandler
Accenture downgraded to Underweight from Neutral at Piper Sandler
10/14/22 JPMorgan
Accenture price target lowered to $306 from $329 at JPMorgan
10/13/22 Wells Fargo
Wells sees some encouraging signs from emerging metaverse app economy
09/27/22 Alliance Global Partners
Perficient upgraded to Buy from Neutral at Alliance Global Partners
GPS Gap
$13.95 /

+0.04 (+0.29%)

12/12/22 Goldman Sachs
Gap upgraded to Buy from Neutral at Goldman Sachs
11/21/22 Deutsche Bank
Gap price target raised to $11 from $8 at Deutsche Bank
11/21/22 Barclays
Gap price target raised to $14 from $9 at Barclays
11/18/22 Jefferies
Gap price target raised to $13 from $11 at Jefferies
TPR Tapestry
$36.75 /

+0.345 (+0.95%)

12/12/22 Goldman Sachs
Tapestry upgraded to Buy from Neutral at Goldman Sachs
11/29/22 JPMorgan
Tapestry price target raised to $47 from $46 at JPMorgan
11/14/22 Citi
Tapestry price target lowered to $40 from $42 at Citi
11/11/22 Morgan Stanley
Tapestry price target lowered to $35 from $39 at Morgan Stanley
LEVI Levi Strauss
$16.65 /

+0.26 (+1.59%)

12/12/22 Goldman Sachs
Levi Strauss downgraded to Neutral from Buy at Goldman Sachs
11/29/22 JPMorgan
Levi Strauss price target lowered to $19 from $20 at JPMorgan
10/10/22 Citi
Levi Strauss price target lowered to $19 from $27 at Citi
10/07/22 Guggenheim
Levi Strauss price target lowered to $27 from $33 at Guggenheim
UA Under Armour
$9.09 /

+0.735 (+8.80%)

WEBR Weber
$8.03 /

+1.525 (+23.46%)

VIVO Meridian Bioscience
$33.57 /

+2.38 (+7.63%)

VIRC Virco
$4.22 /

+0.21 (+5.24%)

UTI Universal Technical
$5.98 /

-1.17 (-16.36%)

UAA Under Armour
$10.44 /

+0.91 (+9.55%)

TPR Tapestry
$36.75 /

+0.345 (+0.95%)

SSNLF Samsung
$40.60 /

+ (+0.00%)

RIVN Rivian Automotive
$26.25 /

-1.04 (-3.81%)

RH RH
$252.26 /

-22.08 (-8.05%)

QCOM Qualcomm
$119.66 /

+0.62 (+0.52%)

PBA Pembina Pipeline
$34.05 /

+0.48 (+1.43%)

NOTV Inotiv
$4.26 /

-1.44 (-25.26%)

MU Micron
$54.12 /

-0.75 (-1.37%)

MSFT Microsoft
$250.15 /

+4.78 (+1.95%)

LEVI Levi Strauss
$16.65 /

+0.26 (+1.59%)

KPTI Karyopharm
$4.00 /

-0.71 (-15.09%)

IAC IAC
$45.95 /

-0.11 (-0.24%)

HZNP Horizon Therapeutics
$112.03 /

+14.68 (+15.08%)

GPS Gap
$13.95 /

+0.04 (+0.29%)

FREE Whole Earth Brands
$4.14 /

-0.105 (-2.47%)

FATE Fate Therapeutics
$16.45 /

-2.44 (-12.92%)

DLNG Dynagas LNG
$2.80 /

-0.19 (-6.35%)

CS Credit Suisse
$3.36 /

-0.02 (-0.59%)

COUP Coupa Software
$78.70 /

+16.62 (+26.77%)

COIN Coinbase
$41.81 /

+1.55 (+3.85%)

BOX Box
$29.93 /

+1.815 (+6.46%)

ATVI Activision Blizzard
$75.33 /

+0.165 (+0.22%)

AMGN Amgen
$275.13 /

-3.455 (-1.24%)

ACN Accenture
$290.81 /

+2.58 (+0.90%)

ACET Adicet Bio
$10.60 /

-6.67 (-38.63%)

  • 21
    Sep
WEBR Weber
$8.03 /

+1.525 (+23.46%)

UAA Under Armour
$10.44 /

+0.91 (+9.55%)

TPR Tapestry
$36.75 /

+0.345 (+0.95%)

SSNLF Samsung
$40.60 /

+ (+0.00%)

RIVN Rivian Automotive
$26.25 /

-1.04 (-3.81%)

QCOM Qualcomm
$119.66 /

+0.62 (+0.52%)

MU Micron
$54.12 /

-0.75 (-1.37%)

MSFT Microsoft
$250.15 /

+4.78 (+1.95%)

IAC IAC
$45.95 /

-0.11 (-0.24%)

HZNP Horizon Therapeutics
$112.03 /

+14.68 (+15.08%)

GPS Gap
$13.95 /

+0.04 (+0.29%)

DLNG Dynagas LNG
$2.80 /

-0.19 (-6.35%)

CS Credit Suisse
$3.36 /

-0.02 (-0.59%)

COUP Coupa Software
$78.70 /

+16.62 (+26.77%)

COIN Coinbase
$41.81 /

+1.55 (+3.85%)

ATVI Activision Blizzard
$75.33 /

+0.165 (+0.22%)

AMGN Amgen
$275.13 /

-3.455 (-1.24%)

ACN Accenture
$290.81 /

+2.58 (+0.90%)

WEBR Weber
$8.03 /

+1.525 (+23.46%)

UTI Universal Technical
$5.98 /

-1.17 (-16.36%)

UAA Under Armour
$10.44 /

+0.91 (+9.55%)

TPR Tapestry
$36.75 /

+0.345 (+0.95%)

SSNLF Samsung
$40.60 /

+ (+0.00%)

RIVN Rivian Automotive
$26.25 /

-1.04 (-3.81%)

RH RH
$252.26 /

-22.08 (-8.05%)

QCOM Qualcomm
$119.66 /

+0.62 (+0.52%)

MU Micron
$54.12 /

-0.75 (-1.37%)

MSFT Microsoft
$250.15 /

+4.78 (+1.95%)

LEVI Levi Strauss
$16.65 /

+0.26 (+1.59%)

IAC IAC
$45.95 /

-0.11 (-0.24%)

HZNP Horizon Therapeutics
$112.03 /

+14.68 (+15.08%)

GPS Gap
$13.95 /

+0.04 (+0.29%)

FATE Fate Therapeutics
$16.45 /

-2.44 (-12.92%)

DLNG Dynagas LNG
$2.80 /

-0.19 (-6.35%)

CS Credit Suisse
$3.36 /

-0.02 (-0.59%)

COUP Coupa Software
$78.70 /

+16.62 (+26.77%)

COIN Coinbase
$41.81 /

+1.55 (+3.85%)

BOX Box
$29.93 /

+1.815 (+6.46%)

ATVI Activision Blizzard
$75.33 /

+0.165 (+0.22%)

AMGN Amgen
$275.13 /

-3.455 (-1.24%)

ACN Accenture
$290.81 /

+2.58 (+0.90%)

WEBR Weber
$8.03 /

+1.525 (+23.46%)

UAA Under Armour
$10.44 /

+0.91 (+9.55%)

TPR Tapestry
$36.75 /

+0.345 (+0.95%)

RIVN Rivian Automotive
$26.25 /

-1.04 (-3.81%)

RH RH
$252.26 /

-22.08 (-8.05%)

QCOM Qualcomm
$119.66 /

+0.62 (+0.52%)

MU Micron
$54.12 /

-0.75 (-1.37%)

MSFT Microsoft
$250.15 /

+4.78 (+1.95%)

LEVI Levi Strauss
$16.65 /

+0.26 (+1.59%)

HZNP Horizon Therapeutics
$112.03 /

+14.68 (+15.08%)

GPS Gap
$13.95 /

+0.04 (+0.29%)

CS Credit Suisse
$3.36 /

-0.02 (-0.59%)

COUP Coupa Software
$78.70 /

+16.62 (+26.77%)

COIN Coinbase
$41.81 /

+1.55 (+3.85%)

BOX Box
$29.93 /

+1.815 (+6.46%)

ATVI Activision Blizzard
$75.33 /

+0.165 (+0.22%)

AMGN Amgen
$275.13 /

-3.455 (-1.24%)

Recommendations
Adicet Bio price target raised to $38 from $34 at H.C. Wainwright » 06:16
12/12/22
12/12
06:16
12/12/22
06:16
ACET

Adicet Bio

$17.27 /

-2.585 (-13.02%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Edward White raised the firm's price target on Adicet Bio to $38 from $34 and keeps a Buy rating on the shares.

ShowHide Related Items >><<
ACET Adicet Bio
$17.27 /

-2.585 (-13.02%)

ACET Adicet Bio
$17.27 /

-2.585 (-13.02%)

09/21/22 JPMorgan
Adicet Bio initiated with Overweight, $23 target at JPMorgan
09/21/22 JPMorgan
Adicet Bio initiated with an Overweight at JPMorgan
03/30/22 SMBC Nikko
Adicet Bio initiated with an Outperform at SMBC Nikko
03/17/22 JMP Securities
Adicet Bio price target lowered to $21 from $30 at JMP Securities
ACET Adicet Bio
$17.27 /

-2.585 (-13.02%)

Hot Stocks
Adicet Bio reports data from ongoing ADI-001 Phase 1 trial » 16:08
12/11/22
12/11
16:08
12/11/22
16:08
ACET

Adicet Bio

$17.27 /

-2.585 (-13.02%)

Adicet Bio announced…

Adicet Bio announced safety and efficacy data from the company's ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell NHL. The company believes these data continue to support the potential of Adicet's investigational gamma delta CAR T cell therapy to provide significant benefit both in terms of anti-tumor activity and safety. Based on the study findings as of a December 5, 2022 data-cut date, Adicet plans to transition ADI-001 into a potentially pivotal program in the second quarter of 2023. Of the 16 evaluable patients, three received ADI-001 at dose level 1, three received ADI-001 at DL2, three received ADI-001 at DL3, one received two infusions of ADI-001 at DL3, and six received ADI-001 at DL4. On an exploratory basis, primarily to understand safety and pharmacokinetics of a second ADI-001 dose, the first and second patient in DL3 while testing negative for minimal residual disease and in CR, received a second DL3 dose, three and two months after the first infusion, respectively. Patients were heavily pretreated with a median number of prior therapies of four and had a poor prognostic outlook based on their median International Prognostic Index score. ADI-001 treatment demonstrated a 75% ORR and 69% CR rate in the study across all dose levels. In five LBCL patients that previously relapsed after prior autologous anti-CD19 CAR T therapy, treatment with ADI-001 demonstrated 100% ORR and CR rate. These patients included a triple-hit high-grade B-cell lymphoma patient, three diffuse large B-cell lymphoma patients, and a double-hit high-grade B-cell lymphoma patient. ADI-001 resulted in CR in patients who previously showed a partial response to autologous CAR T. An 86% CR rate was observed in LBCL patients across DL3 and above. 75% CR rate in LBCL across all dose levels. Both DL2 and DL3 demonstrated a six-month CR rate of 33%; Patient follow up continues in DL4 to assess six-month durability. Circulating ADI-001 cells were visible through day 28 in peripheral blood at DL4. ADI-001 was generally well-tolerated in the study to date. There were no occurrences of dose-limiting toxicities, graft vs host disease, or Grade 3 or higher Cytokine Release Syndrome or immune effector cell-associated neurotoxicity syndrome reported. Enrollment in the Phase 1 clinical study of ADI-001 is currently ongoing to provide additional durability data and further support the recommended Phase 2 dose.

ShowHide Related Items >><<
ACET Adicet Bio
$17.27 /

-2.585 (-13.02%)

ACET Adicet Bio
$17.27 /

-2.585 (-13.02%)

09/21/22 JPMorgan
Adicet Bio initiated with Overweight, $23 target at JPMorgan
09/21/22 JPMorgan
Adicet Bio initiated with an Overweight at JPMorgan
03/30/22 SMBC Nikko
Adicet Bio initiated with an Outperform at SMBC Nikko
03/17/22 JMP Securities
Adicet Bio price target lowered to $21 from $30 at JMP Securities
ACET Adicet Bio
$17.27 /

-2.585 (-13.02%)

Conference/Events
Oppenheimer emerging biotech analysts to hold analyst/industry conference call » 10:25
12/01/22
12/01
10:25
12/01/22
10:25
ACET

Adicet Bio

$18.31 /

+0.12 (+0.66%)

, ACLX

Arcellx

$20.08 /

+0.12 (+0.60%)

, ALLO

Allogene Therapeutics

$9.46 /

-0.38 (-3.86%)

, BMY

Bristol-Myers

$80.52 /

+0.33 (+0.41%)

, CELU

Celularity

$1.78 /

+0.08 (+4.71%)

, CLLS

Cellectis

$2.22 /

+0.01 (+0.45%)

, CRBU

Caribou Biosciences

$9.18 /

-0.145 (-1.55%)

, CRSP

Crispr Therapeutics

$54.83 /

+0.04 (+0.07%)

, DTIL

Precision BioSciences

$1.37 /

+0.01 (+0.74%)

, FATE

Fate Therapeutics

$20.93 /

+0.1 (+0.48%)

, GILD

Gilead

$88.72 /

+0.87 (+0.99%)

, GRCL

Gracell

$3.32 /

+0.07 (+2.15%)

, IPSC

Century Therapeutics

$10.45 /

-0.02 (-0.19%)

, JNJ

Johnson & Johnson

$178.00 /

+0.03 (+0.02%)

, LEGN

Legend Biotech

$51.29 /

-0.035 (-0.07%)

, MBIO

Mustang Bio

/

+

, NKTX

Nkarta

$8.43 /

-0.03 (-0.35%)

, PSTX

Poseida Therapeutics

$4.63 /

+0.09 (+1.98%)

Emerging Biotechnology…

Emerging Biotechnology Analysts Breidenbach and Biegler, along with Drs. Rossi and Braunstein, discuss the evolving treatment landscapes in multiple myeloma and non-hodgkin lymphoma on an Analyst/Industry conference call to be held on December 1 at 11 am.

ShowHide Related Items >><<
PSTX Poseida Therapeutics
$4.63 /

+0.09 (+1.98%)

NKTX Nkarta
$8.43 /

-0.03 (-0.35%)

MBIO Mustang Bio
/

+

LEGN Legend Biotech
$51.29 /

-0.035 (-0.07%)

JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

IPSC Century Therapeutics
$10.45 /

-0.02 (-0.19%)

GRCL Gracell
$3.32 /

+0.07 (+2.15%)

GILD Gilead
$88.72 /

+0.87 (+0.99%)

FATE Fate Therapeutics
$20.93 /

+0.1 (+0.48%)

DTIL Precision BioSciences
$1.37 /

+0.01 (+0.74%)

CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

CRBU Caribou Biosciences
$9.18 /

-0.145 (-1.55%)

CLLS Cellectis
$2.22 /

+0.01 (+0.45%)

CELU Celularity
$1.78 /

+0.08 (+4.71%)

BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

ALLO Allogene Therapeutics
$9.46 /

-0.38 (-3.86%)

ACLX Arcellx
$20.08 /

+0.12 (+0.60%)

ACET Adicet Bio
$18.31 /

+0.12 (+0.66%)

ACET Adicet Bio
$18.31 /

+0.12 (+0.66%)

09/21/22 JPMorgan
Adicet Bio initiated with Overweight, $23 target at JPMorgan
09/21/22 JPMorgan
Adicet Bio initiated with an Overweight at JPMorgan
03/30/22 SMBC Nikko
Adicet Bio initiated with an Outperform at SMBC Nikko
03/17/22 JMP Securities
Adicet Bio price target lowered to $21 from $30 at JMP Securities
ACLX Arcellx
$20.08 /

+0.12 (+0.60%)

10/31/22 Guggenheim
Arcellx initiated with a Buy at Guggenheim
10/27/22 Needham
Arcellx initiated with a Buy at Needham
07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
07/20/22 Canaccord
Arcellx initiated with a Buy at Canaccord
ALLO Allogene Therapeutics
$9.46 /

-0.38 (-3.86%)

11/21/22 H.C. Wainwright
Allogene Therapeutics price target lowered to $29 from $43 at H.C. Wainwright
09/22/22 B. Riley
Allogene Therapeutics price target lowered to $18 from $21 at B. Riley
09/20/22 B. Riley
B. Riley replaces Allogene with Syndax as top pick for 2022
08/10/22 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

11/17/22 Credit Suisse
Bristol-Myers initiated with a Neutral at Credit Suisse
11/17/22 Morgan Stanley
Ventyx Biosciences initiated with an Overweight at Morgan Stanley
11/14/22 BMO Capital
CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital
11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
CELU Celularity
$1.78 /

+0.08 (+4.71%)

08/25/22 Alliance Global Partners
Celularity initiated with a Buy at Alliance Global Partners
08/23/22 Truist
Celularity price target lowered to $6 from $10 at Truist
06/22/22 H.C. Wainwright
Celularity initiated with a Buy at H.C. Wainwright
04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
CLLS Cellectis
$2.22 /

+0.01 (+0.45%)

08/18/22 Citi
Cellectis price target raised to $36 from $34 at Citi
05/18/22 Baird
Cellectis upgraded to Outperform at Baird on valuation 'backstop'
05/18/22 Baird
Cellectis upgraded to Outperform from Neutral at Baird
05/13/22 Barclays
Cellectis price target lowered to $7 from $9 at Barclays
CRBU Caribou Biosciences
$9.18 /

-0.145 (-1.55%)

11/23/22 Citi
Caribou Biosciences price target lowered to $37 from $38 at Citi
08/29/22 Citi
Caribou Biosciences price target lowered to $38 from $39 at Citi
08/18/22 H.C. Wainwright
Caribou Biosciences price target lowered to $27 from $28 at H.C. Wainwright
05/12/22 Citi
Caribou Biosciences price target raised to $39 from $29 at Citi
CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

11/23/22 Citi
Crispr Therapeutics price target lowered to $63 from $83 at Citi
11/02/22 Barclays
Crispr Therapeutics price target lowered to $61 from $88 at Barclays
11/02/22 Credit Suisse
Crispr Therapeutics price target lowered to $78 from $90 at Credit Suisse
10/11/22 Morgan Stanley
Crispr Therapeutics initiated with an Underweight at Morgan Stanley
DTIL Precision BioSciences
$1.37 /

+0.01 (+0.74%)

11/10/22 H.C. Wainwright
Precision BioSciences price target lowered to $17 from $20 at H.C. Wainwright
06/16/22 BMO Capital
Precision BioSciences initiated with an Outperform at BMO Capital
06/09/22 William Blair
Precision BioSciences downgraded to Market Perform at William Blair
12/13/21 BTIG
Precision BioSciences price target raised to $20 from $16 at BTIG
FATE Fate Therapeutics
$20.93 /

+0.1 (+0.48%)

11/16/22 Citi
Fate Therapeutics price target lowered to $80 from $87 at Citi
11/04/22 Cantor Fitzgerald
Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/10/22 Canaccord
Fate Therapeutics initiated with a Buy at Canaccord
08/18/22 Wells Fargo
Fate Therapeutics assumed with an Overweight at Wells Fargo
GILD Gilead
$88.72 /

+0.87 (+0.99%)

12/01/22 Oppenheimer
Gilead price target raised to $105 from $95 at Oppenheimer
11/22/22 Guggenheim
MacroGenics upgraded to Buy at Guggenheim ahead of near-term catalysts
11/09/22 Argus
Gilead price target raised to $100 from $70 at Argus
11/08/22 Cowen
Gilead price target raised to $90 from $80 at Cowen
GRCL Gracell
$3.32 /

+0.07 (+2.15%)

09/22/22 Citi
Gracell initiated with a Buy at Citi
08/18/22 Wells Fargo
Gracell assumed with an Overweight at Wells Fargo
06/01/22 Cantor Fitzgerald
Gracell initiated with an Overweight at Cantor Fitzgerald
05/27/22 Piper Sandler
Gracell price target lowered to $10 from $25 at Piper Sandler
IPSC Century Therapeutics
$10.45 /

-0.02 (-0.19%)

11/14/22 H.C. Wainwright
Century Therapeutics price target lowered to $25 from $27 at H.C. Wainwright
11/11/22 Piper Sandler
Century Therapeutics price target raised to $24 at Piper after R&D day
10/31/22 Guggenheim
Century Therapeutics initiated with a Buy at Guggenheim
10/10/22 Canaccord
Century Therapeutics initiated with a Buy at Canaccord
JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

12/01/22 Jefferies
Horizon Therapeutics price target raised to $125 from $101 at Jefferies
12/01/22 Morgan Stanley
Johnson & Johnson price target raised to $178 from $170 at Morgan Stanley
11/30/22 Wells Fargo
Horizon Therapeutics takeover value could be $135/share, says Wells Fargo
11/29/22 Craig-Hallum
Craig-Hallum sees potential for competing Apollo Endosurgery bids
LEGN Legend Biotech
$51.29 /

-0.035 (-0.07%)

11/01/22 Evercore ISI
Legend Biotech initiated with an Outperform at Evercore ISI
11/01/22 Cowen
Cowen starts Legend Biotech with an Outperform on Carvykti potential
11/01/22 Cowen
Legend Biotech initiated with an Outperform at Cowen
MBIO Mustang Bio
/

+

11/16/22 BTIG
Mustang Bio price target lowered to $4 from $8 at BTIG
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
07/14/22 B. Riley
Mustang Bio price target lowered to $4 from $5 at B. Riley
05/23/22 B. Riley
Mustang Bio price target lowered to $5 from $6 at B. Riley
NKTX Nkarta
$8.43 /

-0.03 (-0.35%)

11/16/22 Mizuho
Nkarta price target lowered to $26 from $81 at Mizuho
11/10/22 Oppenheimer
Nkarta price target lowered to $36 from $50 at Oppenheimer
10/10/22 Canaccord
Nkarta initiated with a Buy at Canaccord
08/12/22 Cantor Fitzgerald
Nkarta price target lowered to $38 from $60 at Cantor Fitzgerald
PSTX Poseida Therapeutics
$4.63 /

+0.09 (+1.98%)

11/11/22 BTIG
Poseida Therapeutics price target lowered to $14 from $20 at BTIG
08/09/22 Piper Sandler
Poseida Therapeutics price target raised to $11 from $9 at Piper Sandler
05/13/22 BTIG
Poseida Therapeutics price target lowered to $20 from $40 at BTIG
05/13/22 Piper Sandler
Poseida Therapeutics price target lowered to $9 from $19 at Piper Sandler
PSTX Poseida Therapeutics
$4.63 /

+0.09 (+1.98%)

NKTX Nkarta
$8.43 /

-0.03 (-0.35%)

MBIO Mustang Bio
/

+

JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

IPSC Century Therapeutics
$10.45 /

-0.02 (-0.19%)

GRCL Gracell
$3.32 /

+0.07 (+2.15%)

GILD Gilead
$88.72 /

+0.87 (+0.99%)

FATE Fate Therapeutics
$20.93 /

+0.1 (+0.48%)

DTIL Precision BioSciences
$1.37 /

+0.01 (+0.74%)

CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

CRBU Caribou Biosciences
$9.18 /

-0.145 (-1.55%)

CLLS Cellectis
$2.22 /

+0.01 (+0.45%)

CELU Celularity
$1.78 /

+0.08 (+4.71%)

BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

ALLO Allogene Therapeutics
$9.46 /

-0.38 (-3.86%)

ACLX Arcellx
$20.08 /

+0.12 (+0.60%)

ACET Adicet Bio
$18.31 /

+0.12 (+0.66%)

  • 04
    Aug
  • 27
    Jul
  • 17
    Jun
  • 26
    Apr
  • 04
    Feb
  • 16
    Dec
  • 08
    Dec
JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

LEGN Legend Biotech
$51.29 /

-0.035 (-0.07%)

JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

GRCL Gracell
$3.32 /

+0.07 (+2.15%)

GILD Gilead
$88.72 /

+0.87 (+0.99%)

FATE Fate Therapeutics
$20.93 /

+0.1 (+0.48%)

CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

CRBU Caribou Biosciences
$9.18 /

-0.145 (-1.55%)

BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

ALLO Allogene Therapeutics
$9.46 /

-0.38 (-3.86%)

ACLX Arcellx
$20.08 /

+0.12 (+0.60%)

ACET Adicet Bio
$18.31 /

+0.12 (+0.66%)

JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

IPSC Century Therapeutics
$10.45 /

-0.02 (-0.19%)

GILD Gilead
$88.72 /

+0.87 (+0.99%)

CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

CELU Celularity
$1.78 /

+0.08 (+4.71%)

BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

ACLX Arcellx
$20.08 /

+0.12 (+0.60%)

Conference/Events
Oppenheimer emerging biotech analysts to hold analyst/industry conference call » 04:55
12/01/22
12/01
04:55
12/01/22
04:55
ACET

Adicet Bio

$18.20 /

+0.42 (+2.36%)

, ACLX

Arcellx

$19.90 /

+ (+0.00%)

, ALLO

Allogene Therapeutics

$9.84 /

+0.56 (+6.03%)

, BMY

Bristol-Myers

$80.19 /

+1.18 (+1.49%)

, CELU

Celularity

$1.71 /

+0.035 (+2.10%)

, CLLS

Cellectis

$2.22 /

+0.04 (+1.83%)

, CRBU

Caribou Biosciences

$9.33 /

+0.985 (+11.81%)

, CRSP

Crispr Therapeutics

$54.69 /

+1.78 (+3.36%)

, DTIL

Precision BioSciences

$1.36 /

+0.06 (+4.62%)

, FATE

Fate Therapeutics

$20.84 /

+1.07 (+5.41%)

, GILD

Gilead

$87.85 /

+2.09 (+2.44%)

, GRCL

Gracell

$3.28 /

+0.04 (+1.23%)

, IPSC

Century Therapeutics

$10.48 /

+0.14 (+1.35%)

, JNJ

Johnson & Johnson

$177.94 /

+1.895 (+1.08%)

, LEGN

Legend Biotech

$51.25 /

+2.64 (+5.43%)

, MBIO

Mustang Bio

/

+

, NKTX

Nkarta

$8.46 /

+0.365 (+4.51%)

, PSTX

Poseida Therapeutics

$4.54 /

+0.125 (+2.83%)

Emerging Biotechnology…

Emerging Biotechnology Analysts Breidenbach and Biegler, along with Drs. Rossi and Braunstein, discuss the evolving treatment landscapes in multiple myeloma and non-hodgkin lymphoma on an Analyst/Industry conference call to be held on December 1 at 11 am.

ShowHide Related Items >><<
PSTX Poseida Therapeutics
$4.54 /

+0.125 (+2.83%)

NKTX Nkarta
$8.46 /

+0.365 (+4.51%)

MBIO Mustang Bio
/

+

LEGN Legend Biotech
$51.25 /

+2.64 (+5.43%)

JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

IPSC Century Therapeutics
$10.48 /

+0.14 (+1.35%)

GRCL Gracell
$3.28 /

+0.04 (+1.23%)

GILD Gilead
$87.85 /

+2.09 (+2.44%)

FATE Fate Therapeutics
$20.84 /

+1.07 (+5.41%)

DTIL Precision BioSciences
$1.36 /

+0.06 (+4.62%)

CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

CRBU Caribou Biosciences
$9.33 /

+0.985 (+11.81%)

CLLS Cellectis
$2.22 /

+0.04 (+1.83%)

CELU Celularity
$1.71 /

+0.035 (+2.10%)

BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

ALLO Allogene Therapeutics
$9.84 /

+0.56 (+6.03%)

ACLX Arcellx
$19.90 /

+ (+0.00%)

ACET Adicet Bio
$18.20 /

+0.42 (+2.36%)

ACET Adicet Bio
$18.20 /

+0.42 (+2.36%)

09/21/22 JPMorgan
Adicet Bio initiated with Overweight, $23 target at JPMorgan
09/21/22 JPMorgan
Adicet Bio initiated with an Overweight at JPMorgan
03/30/22 SMBC Nikko
Adicet Bio initiated with an Outperform at SMBC Nikko
03/17/22 JMP Securities
Adicet Bio price target lowered to $21 from $30 at JMP Securities
ACLX Arcellx
$19.90 /

+ (+0.00%)

10/31/22 Guggenheim
Arcellx initiated with a Buy at Guggenheim
10/27/22 Needham
Arcellx initiated with a Buy at Needham
07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
07/20/22 Canaccord
Arcellx initiated with a Buy at Canaccord
ALLO Allogene Therapeutics
$9.84 /

+0.56 (+6.03%)

11/21/22 H.C. Wainwright
Allogene Therapeutics price target lowered to $29 from $43 at H.C. Wainwright
09/22/22 B. Riley
Allogene Therapeutics price target lowered to $18 from $21 at B. Riley
09/20/22 B. Riley
B. Riley replaces Allogene with Syndax as top pick for 2022
08/10/22 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

11/17/22 Credit Suisse
Bristol-Myers initiated with a Neutral at Credit Suisse
11/17/22 Morgan Stanley
Ventyx Biosciences initiated with an Overweight at Morgan Stanley
11/14/22 BMO Capital
CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital
11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
CELU Celularity
$1.71 /

+0.035 (+2.10%)

08/25/22 Alliance Global Partners
Celularity initiated with a Buy at Alliance Global Partners
08/23/22 Truist
Celularity price target lowered to $6 from $10 at Truist
06/22/22 H.C. Wainwright
Celularity initiated with a Buy at H.C. Wainwright
04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
CLLS Cellectis
$2.22 /

+0.04 (+1.83%)

08/18/22 Citi
Cellectis price target raised to $36 from $34 at Citi
05/18/22 Baird
Cellectis upgraded to Outperform at Baird on valuation 'backstop'
05/18/22 Baird
Cellectis upgraded to Outperform from Neutral at Baird
05/13/22 Barclays
Cellectis price target lowered to $7 from $9 at Barclays
CRBU Caribou Biosciences
$9.33 /

+0.985 (+11.81%)

11/23/22 Citi
Caribou Biosciences price target lowered to $37 from $38 at Citi
08/29/22 Citi
Caribou Biosciences price target lowered to $38 from $39 at Citi
08/18/22 H.C. Wainwright
Caribou Biosciences price target lowered to $27 from $28 at H.C. Wainwright
05/12/22 Citi
Caribou Biosciences price target raised to $39 from $29 at Citi
CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

11/23/22 Citi
Crispr Therapeutics price target lowered to $63 from $83 at Citi
11/02/22 Barclays
Crispr Therapeutics price target lowered to $61 from $88 at Barclays
11/02/22 Credit Suisse
Crispr Therapeutics price target lowered to $78 from $90 at Credit Suisse
10/11/22 Morgan Stanley
Crispr Therapeutics initiated with an Underweight at Morgan Stanley
DTIL Precision BioSciences
$1.36 /

+0.06 (+4.62%)

11/10/22 H.C. Wainwright
Precision BioSciences price target lowered to $17 from $20 at H.C. Wainwright
06/16/22 BMO Capital
Precision BioSciences initiated with an Outperform at BMO Capital
06/09/22 William Blair
Precision BioSciences downgraded to Market Perform at William Blair
12/13/21 BTIG
Precision BioSciences price target raised to $20 from $16 at BTIG
FATE Fate Therapeutics
$20.84 /

+1.07 (+5.41%)

11/16/22 Citi
Fate Therapeutics price target lowered to $80 from $87 at Citi
11/04/22 Cantor Fitzgerald
Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/10/22 Canaccord
Fate Therapeutics initiated with a Buy at Canaccord
08/18/22 Wells Fargo
Fate Therapeutics assumed with an Overweight at Wells Fargo
GILD Gilead
$87.85 /

+2.09 (+2.44%)

11/22/22 Guggenheim
MacroGenics upgraded to Buy at Guggenheim ahead of near-term catalysts
11/09/22 Argus
Gilead price target raised to $100 from $70 at Argus
11/08/22 Cowen
Gilead price target raised to $90 from $80 at Cowen
11/08/22 Mizuho
Gilead price target raised to $88 from $75 at Mizuho
GRCL Gracell
$3.28 /

+0.04 (+1.23%)

09/22/22 Citi
Gracell initiated with a Buy at Citi
08/18/22 Wells Fargo
Gracell assumed with an Overweight at Wells Fargo
06/01/22 Cantor Fitzgerald
Gracell initiated with an Overweight at Cantor Fitzgerald
05/27/22 Piper Sandler
Gracell price target lowered to $10 from $25 at Piper Sandler
IPSC Century Therapeutics
$10.48 /

+0.14 (+1.35%)

11/14/22 H.C. Wainwright
Century Therapeutics price target lowered to $25 from $27 at H.C. Wainwright
11/11/22 Piper Sandler
Century Therapeutics price target raised to $24 at Piper after R&D day
10/31/22 Guggenheim
Century Therapeutics initiated with a Buy at Guggenheim
10/10/22 Canaccord
Century Therapeutics initiated with a Buy at Canaccord
JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

11/30/22 Wells Fargo
Horizon Therapeutics takeover value could be $135/share, says Wells Fargo
11/29/22 Craig-Hallum
Craig-Hallum sees potential for competing Apollo Endosurgery bids
11/28/22 Morgan Stanley
Genmab risk/reward favorable into arbitration ruling, says Morgan Stanley
11/17/22 Credit Suisse
Johnson & Johnson initiated with a Neutral at Credit Suisse
LEGN Legend Biotech
$51.25 /

+2.64 (+5.43%)

11/01/22 Evercore ISI
Legend Biotech initiated with an Outperform at Evercore ISI
11/01/22 Cowen
Cowen starts Legend Biotech with an Outperform on Carvykti potential
11/01/22 Cowen
Legend Biotech initiated with an Outperform at Cowen
MBIO Mustang Bio
/

+

11/16/22 BTIG
Mustang Bio price target lowered to $4 from $8 at BTIG
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
07/14/22 B. Riley
Mustang Bio price target lowered to $4 from $5 at B. Riley
05/23/22 B. Riley
Mustang Bio price target lowered to $5 from $6 at B. Riley
NKTX Nkarta
$8.46 /

+0.365 (+4.51%)

11/16/22 Mizuho
Nkarta price target lowered to $26 from $81 at Mizuho
11/10/22 Oppenheimer
Nkarta price target lowered to $36 from $50 at Oppenheimer
10/10/22 Canaccord
Nkarta initiated with a Buy at Canaccord
08/12/22 Cantor Fitzgerald
Nkarta price target lowered to $38 from $60 at Cantor Fitzgerald
PSTX Poseida Therapeutics
$4.54 /

+0.125 (+2.83%)

11/11/22 BTIG
Poseida Therapeutics price target lowered to $14 from $20 at BTIG
08/09/22 Piper Sandler
Poseida Therapeutics price target raised to $11 from $9 at Piper Sandler
05/13/22 BTIG
Poseida Therapeutics price target lowered to $20 from $40 at BTIG
05/13/22 Piper Sandler
Poseida Therapeutics price target lowered to $9 from $19 at Piper Sandler
PSTX Poseida Therapeutics
$4.54 /

+0.125 (+2.83%)

NKTX Nkarta
$8.46 /

+0.365 (+4.51%)

MBIO Mustang Bio
/

+

LEGN Legend Biotech
$51.25 /

+2.64 (+5.43%)

JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

IPSC Century Therapeutics
$10.48 /

+0.14 (+1.35%)

GRCL Gracell
$3.28 /

+0.04 (+1.23%)

GILD Gilead
$87.85 /

+2.09 (+2.44%)

FATE Fate Therapeutics
$20.84 /

+1.07 (+5.41%)

DTIL Precision BioSciences
$1.36 /

+0.06 (+4.62%)

CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

CRBU Caribou Biosciences
$9.33 /

+0.985 (+11.81%)

CLLS Cellectis
$2.22 /

+0.04 (+1.83%)

CELU Celularity
$1.71 /

+0.035 (+2.10%)

BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

ALLO Allogene Therapeutics
$9.84 /

+0.56 (+6.03%)

ACLX Arcellx
$19.90 /

+ (+0.00%)

ACET Adicet Bio
$18.20 /

+0.42 (+2.36%)

  • 04
    Aug
  • 27
    Jul
  • 17
    Jun
  • 26
    Apr
  • 04
    Feb
  • 16
    Dec
  • 08
    Dec
JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

LEGN Legend Biotech
$51.25 /

+2.64 (+5.43%)

JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

GRCL Gracell
$3.28 /

+0.04 (+1.23%)

GILD Gilead
$87.85 /

+2.09 (+2.44%)

FATE Fate Therapeutics
$20.84 /

+1.07 (+5.41%)

CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

CRBU Caribou Biosciences
$9.33 /

+0.985 (+11.81%)

BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

ALLO Allogene Therapeutics
$9.84 /

+0.56 (+6.03%)

ACLX Arcellx
$19.90 /

+ (+0.00%)

ACET Adicet Bio
$18.20 /

+0.42 (+2.36%)

JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

IPSC Century Therapeutics
$10.48 /

+0.14 (+1.35%)

GILD Gilead
$87.85 /

+2.09 (+2.44%)

CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

CELU Celularity
$1.71 /

+0.035 (+2.10%)

BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

ACLX Arcellx
$19.90 /

+ (+0.00%)

Hot Stocks
Adicet Bio appoints Nancy Boman, M.D Chief Regulatory Officer » 07:05
11/29/22
11/29
07:05
11/29/22
07:05
ACET

Adicet Bio

$16.71 /

-0.41 (-2.39%)

Adicet Bio announced the…

Adicet Bio announced the appointment of Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer. Dr. Boman will spearhead Adicet's regulatory strategy to further advance existing and new pipeline opportunities for the Company's gamma delta T cell platform. "We are incredibly excited to welcome Nancy to the Adicet team," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "Her vast experience in successfully filing marketing applications for more than 15 products, including in hematologic malignancies, such as non-Hodgkin's lymphoma, is perfectly aligned with our plan to initiate a potentially pivotal program for ADI-001 in the first half of 2023. Nancy's leadership in building and expanding global regulatory operations particularly in the oncology field, including in solid tumors, is an asset to the team and positions us well as we expect to submit an IND application for ADI-925 in the second half of 2023 and potentially advance other pipeline programs, as disclosed in our recent R&D event, to regulatory submissions and clinical trials."

ShowHide Related Items >><<
ACET Adicet Bio
$16.71 /

-0.41 (-2.39%)

ACET Adicet Bio
$16.71 /

-0.41 (-2.39%)

09/21/22 JPMorgan
Adicet Bio initiated with Overweight, $23 target at JPMorgan
09/21/22 JPMorgan
Adicet Bio initiated with an Overweight at JPMorgan
03/30/22 SMBC Nikko
Adicet Bio initiated with an Outperform at SMBC Nikko
03/17/22 JMP Securities
Adicet Bio price target lowered to $21 from $30 at JMP Securities
ACET Adicet Bio
$16.71 /

-0.41 (-2.39%)

  • 08
    Dec
ACET Adicet Bio
$16.71 /

-0.41 (-2.39%)

Conference/Events
Oppenheimer emerging biotech analysts to hold analyst/industry conference call » 16:34
11/28/22
11/28
16:34
11/28/22
16:34
ACET

Adicet Bio

$16.71 /

-0.41 (-2.39%)

, ACLX

Arcellx

$20.13 /

-1.52 (-7.02%)

, ALLO

Allogene Therapeutics

$10.27 /

-0.515 (-4.78%)

, BMY

Bristol-Myers

$79.13 /

+ (+0.00%)

, CELU

Celularity

$1.63 /

+0.04 (+2.52%)

, CLLS

Cellectis

$2.24 /

-0.11 (-4.68%)

, CRBU

Caribou Biosciences

$8.53 /

-0.32 (-3.62%)

, CRSP

Crispr Therapeutics

$53.39 /

-1.54 (-2.80%)

, DTIL

Precision BioSciences

$1.35 /

-0.045 (-3.23%)

, FATE

Fate Therapeutics

$19.28 /

-0.54 (-2.72%)

, GILD

Gilead

$85.23 /

-1.04 (-1.21%)

, GRCL

Gracell

$3.13 /

-0.475 (-13.18%)

, IPSC

Century Therapeutics

$10.35 /

-0.15 (-1.43%)

, JNJ

Johnson & Johnson

$177.31 /

+0.11 (+0.06%)

, LEGN

Legend Biotech

$48.12 /

+0.09 (+0.19%)

, MBIO

Mustang Bio

/

+

, NKTX

Nkarta

$8.09 /

-0.525 (-6.10%)

, PSTX

Poseida Therapeutics

$4.06 /

-0.34 (-7.73%)

Emerging Biotechnology…

Emerging Biotechnology Analysts Breidenbach and Biegler, along with Drs. Rossi and Braunstein, discuss the evolving treatment landscapes in multiple myeloma and non-hodgkin lymphoma on an Analyst/Industry conference call to be held on December 1 at 11 am.

ShowHide Related Items >><<
PSTX Poseida Therapeutics
$4.06 /

-0.34 (-7.73%)

NKTX Nkarta
$8.09 /

-0.525 (-6.10%)

MBIO Mustang Bio
/

+

LEGN Legend Biotech
$48.12 /

+0.09 (+0.19%)

JNJ Johnson & Johnson
$177.31 /

+0.11 (+0.06%)

IPSC Century Therapeutics
$10.35 /

-0.15 (-1.43%)

GRCL Gracell
$3.13 /

-0.475 (-13.18%)

GILD Gilead
$85.23 /

-1.04 (-1.21%)

FATE Fate Therapeutics
$19.28 /

-0.54 (-2.72%)

DTIL Precision BioSciences
$1.35 /

-0.045 (-3.23%)

CRSP Crispr Therapeutics
$53.39 /

-1.54 (-2.80%)

CRBU Caribou Biosciences
$8.53 /

-0.32 (-3.62%)

CLLS Cellectis
$2.24 /

-0.11 (-4.68%)

CELU Celularity
$1.63 /

+0.04 (+2.52%)

BMY Bristol-Myers
$79.13 /

+ (+0.00%)

ALLO Allogene Therapeutics
$10.27 /

-0.515 (-4.78%)

ACLX Arcellx
$20.13 /

-1.52 (-7.02%)

ACET Adicet Bio
$16.71 /

-0.41 (-2.39%)

ACET Adicet Bio
$16.71 /

-0.41 (-2.39%)

09/21/22 JPMorgan
Adicet Bio initiated with Overweight, $23 target at JPMorgan
09/21/22 JPMorgan
Adicet Bio initiated with an Overweight at JPMorgan
03/30/22 SMBC Nikko
Adicet Bio initiated with an Outperform at SMBC Nikko
03/17/22 JMP Securities
Adicet Bio price target lowered to $21 from $30 at JMP Securities
ACLX Arcellx
$20.13 /

-1.52 (-7.02%)

10/31/22 Guggenheim
Arcellx initiated with a Buy at Guggenheim
10/27/22 Needham
Arcellx initiated with a Buy at Needham
07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
07/20/22 Canaccord
Arcellx initiated with a Buy at Canaccord
ALLO Allogene Therapeutics
$10.27 /

-0.515 (-4.78%)

11/21/22 H.C. Wainwright
Allogene Therapeutics price target lowered to $29 from $43 at H.C. Wainwright
09/22/22 B. Riley
Allogene Therapeutics price target lowered to $18 from $21 at B. Riley
09/20/22 B. Riley
B. Riley replaces Allogene with Syndax as top pick for 2022
08/10/22 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
BMY Bristol-Myers
$79.13 /

+ (+0.00%)

11/17/22 Credit Suisse
Bristol-Myers initiated with a Neutral at Credit Suisse
11/17/22 Morgan Stanley
Ventyx Biosciences initiated with an Overweight at Morgan Stanley
11/14/22 BMO Capital
CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital
11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
CELU Celularity
$1.63 /

+0.04 (+2.52%)

08/25/22 Alliance Global Partners
Celularity initiated with a Buy at Alliance Global Partners
08/23/22 Truist
Celularity price target lowered to $6 from $10 at Truist
06/22/22 H.C. Wainwright
Celularity initiated with a Buy at H.C. Wainwright
04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
CLLS Cellectis
$2.24 /

-0.11 (-4.68%)

08/18/22 Citi
Cellectis price target raised to $36 from $34 at Citi
05/18/22 Baird
Cellectis upgraded to Outperform at Baird on valuation 'backstop'
05/18/22 Baird
Cellectis upgraded to Outperform from Neutral at Baird
05/13/22 Barclays
Cellectis price target lowered to $7 from $9 at Barclays
CRBU Caribou Biosciences
$8.53 /

-0.32 (-3.62%)

11/23/22 Citi
Caribou Biosciences price target lowered to $37 from $38 at Citi
08/29/22 Citi
Caribou Biosciences price target lowered to $38 from $39 at Citi
08/18/22 H.C. Wainwright
Caribou Biosciences price target lowered to $27 from $28 at H.C. Wainwright
05/12/22 Citi
Caribou Biosciences price target raised to $39 from $29 at Citi
CRSP Crispr Therapeutics
$53.39 /

-1.54 (-2.80%)

11/23/22 Citi
Crispr Therapeutics price target lowered to $63 from $83 at Citi
11/02/22 Barclays
Crispr Therapeutics price target lowered to $61 from $88 at Barclays
11/02/22 Credit Suisse
Crispr Therapeutics price target lowered to $78 from $90 at Credit Suisse
10/11/22 Morgan Stanley
Crispr Therapeutics initiated with an Underweight at Morgan Stanley
DTIL Precision BioSciences
$1.35 /

-0.045 (-3.23%)

11/10/22 H.C. Wainwright
Precision BioSciences price target lowered to $17 from $20 at H.C. Wainwright
06/16/22 BMO Capital
Precision BioSciences initiated with an Outperform at BMO Capital
06/09/22 William Blair
Precision BioSciences downgraded to Market Perform at William Blair
12/13/21 BTIG
Precision BioSciences price target raised to $20 from $16 at BTIG
FATE Fate Therapeutics
$19.28 /

-0.54 (-2.72%)

11/16/22 Citi
Fate Therapeutics price target lowered to $80 from $87 at Citi
11/04/22 Cantor Fitzgerald
Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/10/22 Canaccord
Fate Therapeutics initiated with a Buy at Canaccord
08/18/22 Wells Fargo
Fate Therapeutics assumed with an Overweight at Wells Fargo
GILD Gilead
$85.23 /

-1.04 (-1.21%)

11/22/22 Guggenheim
MacroGenics upgraded to Buy at Guggenheim ahead of near-term catalysts
11/09/22 Argus
Gilead price target raised to $100 from $70 at Argus
11/08/22 Cowen
Gilead price target raised to $90 from $80 at Cowen
11/08/22 Mizuho
Gilead price target raised to $88 from $75 at Mizuho
GRCL Gracell
$3.13 /

-0.475 (-13.18%)

09/22/22 Citi
Gracell initiated with a Buy at Citi
08/18/22 Wells Fargo
Gracell assumed with an Overweight at Wells Fargo
06/01/22 Cantor Fitzgerald
Gracell initiated with an Overweight at Cantor Fitzgerald
05/27/22 Piper Sandler
Gracell price target lowered to $10 from $25 at Piper Sandler
IPSC Century Therapeutics
$10.35 /

-0.15 (-1.43%)

11/14/22 H.C. Wainwright
Century Therapeutics price target lowered to $25 from $27 at H.C. Wainwright
11/11/22 Piper Sandler
Century Therapeutics price target raised to $24 at Piper after R&D day
10/31/22 Guggenheim
Century Therapeutics initiated with a Buy at Guggenheim
10/10/22 Canaccord
Century Therapeutics initiated with a Buy at Canaccord
JNJ Johnson & Johnson
$177.31 /

+0.11 (+0.06%)

11/17/22 Credit Suisse
Johnson & Johnson initiated with a Neutral at Credit Suisse
11/02/22 Morgan Stanley
Abiomed upgraded to Equal Weight from Underweight at Morgan Stanley
11/02/22 Deutsche Bank
Abiomed downgraded to Hold from Buy at Deutsche Bank
11/01/22 Piper Sandler
Abiomed downgraded to Neutral from Overweight at Piper Sandler
LEGN Legend Biotech
$48.12 /

+0.09 (+0.19%)

11/01/22 Evercore ISI
Legend Biotech initiated with an Outperform at Evercore ISI
11/01/22 Cowen
Cowen starts Legend Biotech with an Outperform on Carvykti potential
11/01/22 Cowen
Legend Biotech initiated with an Outperform at Cowen
MBIO Mustang Bio
/

+

11/16/22 BTIG
Mustang Bio price target lowered to $4 from $8 at BTIG
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
07/14/22 B. Riley
Mustang Bio price target lowered to $4 from $5 at B. Riley
05/23/22 B. Riley
Mustang Bio price target lowered to $5 from $6 at B. Riley
NKTX Nkarta
$8.09 /

-0.525 (-6.10%)

11/16/22 Mizuho
Nkarta price target lowered to $26 from $81 at Mizuho
11/10/22 Oppenheimer
Nkarta price target lowered to $36 from $50 at Oppenheimer
10/10/22 Canaccord
Nkarta initiated with a Buy at Canaccord
08/12/22 Cantor Fitzgerald
Nkarta price target lowered to $38 from $60 at Cantor Fitzgerald
PSTX Poseida Therapeutics
$4.06 /

-0.34 (-7.73%)

11/11/22 BTIG
Poseida Therapeutics price target lowered to $14 from $20 at BTIG
08/09/22 Piper Sandler
Poseida Therapeutics price target raised to $11 from $9 at Piper Sandler
05/13/22 BTIG
Poseida Therapeutics price target lowered to $20 from $40 at BTIG
05/13/22 Piper Sandler
Poseida Therapeutics price target lowered to $9 from $19 at Piper Sandler
PSTX Poseida Therapeutics
$4.06 /

-0.34 (-7.73%)

NKTX Nkarta
$8.09 /

-0.525 (-6.10%)

MBIO Mustang Bio
/

+

LEGN Legend Biotech
$48.12 /

+0.09 (+0.19%)

JNJ Johnson & Johnson
$177.31 /

+0.11 (+0.06%)

IPSC Century Therapeutics
$10.35 /

-0.15 (-1.43%)

GRCL Gracell
$3.13 /

-0.475 (-13.18%)

GILD Gilead
$85.23 /

-1.04 (-1.21%)

FATE Fate Therapeutics
$19.28 /

-0.54 (-2.72%)

DTIL Precision BioSciences
$1.35 /

-0.045 (-3.23%)

CRSP Crispr Therapeutics
$53.39 /

-1.54 (-2.80%)

CRBU Caribou Biosciences
$8.53 /

-0.32 (-3.62%)

CLLS Cellectis
$2.24 /

-0.11 (-4.68%)

CELU Celularity
$1.63 /

+0.04 (+2.52%)

BMY Bristol-Myers
$79.13 /

+ (+0.00%)

ALLO Allogene Therapeutics
$10.27 /

-0.515 (-4.78%)

ACLX Arcellx
$20.13 /

-1.52 (-7.02%)

ACET Adicet Bio
$16.71 /

-0.41 (-2.39%)

  • 04
    Aug
  • 27
    Jul
  • 17
    Jun
  • 26
    Apr
  • 04
    Feb
  • 16
    Dec
  • 08
    Dec
JNJ Johnson & Johnson
$177.31 /

+0.11 (+0.06%)

CRSP Crispr Therapeutics
$53.39 /

-1.54 (-2.80%)

BMY Bristol-Myers
$79.13 /

+ (+0.00%)

LEGN Legend Biotech
$48.12 /

+0.09 (+0.19%)

JNJ Johnson & Johnson
$177.31 /

+0.11 (+0.06%)

GRCL Gracell
$3.13 /

-0.475 (-13.18%)

GILD Gilead
$85.23 /

-1.04 (-1.21%)

FATE Fate Therapeutics
$19.28 /

-0.54 (-2.72%)

CRSP Crispr Therapeutics
$53.39 /

-1.54 (-2.80%)

CRBU Caribou Biosciences
$8.53 /

-0.32 (-3.62%)

BMY Bristol-Myers
$79.13 /

+ (+0.00%)

ALLO Allogene Therapeutics
$10.27 /

-0.515 (-4.78%)

ACLX Arcellx
$20.13 /

-1.52 (-7.02%)

ACET Adicet Bio
$16.71 /

-0.41 (-2.39%)

JNJ Johnson & Johnson
$177.31 /

+0.11 (+0.06%)

IPSC Century Therapeutics
$10.35 /

-0.15 (-1.43%)

GILD Gilead
$85.23 /

-1.04 (-1.21%)

CRSP Crispr Therapeutics
$53.39 /

-1.54 (-2.80%)

CELU Celularity
$1.63 /

+0.04 (+2.52%)

BMY Bristol-Myers
$79.13 /

+ (+0.00%)

ACLX Arcellx
$20.13 /

-1.52 (-7.02%)

Earnings
Adicet Bio reports Q3 EPS (53c), consensus (53c) » 16:34
11/08/22
11/08
16:34
11/08/22
16:34
ACET

Adicet Bio

$19.27 /

+0.135 (+0.71%)

Cash and cash equivalents…

Cash and cash equivalents were $282.7 million as of September 30, 2022, compared to $277.5 million as of December 31, 2021. The Company expects that current cash and cash equivalents as of September 30, 2022, will be sufficient to fund its operating expenses into the first half of 2025. "We have continued to make very encouraging clinical progress in 2022, reporting promising safety and efficacy data for our lead candidate ADI-001 for the potential treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma," said Chen Schor, CEO. "We're currently enrolling patients in dose level 4 and expect to initiate a potentially pivotal program with the recommended Phase 2 dose for ADI-001 in the first half of 2023. We look forward to providing additional clinical data on ADI-001 at the American Society of Hematology Annual Meeting in December as well as promising preclinical data on our emerging pipeline programs at the upcoming Society for Immunotherapy of Cancer's Annual Meeting and our upcoming R&D event."

ShowHide Related Items >><<
ACET Adicet Bio
$19.27 /

+0.135 (+0.71%)

ACET Adicet Bio
$19.27 /

+0.135 (+0.71%)

09/21/22 JPMorgan
Adicet Bio initiated with Overweight, $23 target at JPMorgan
09/21/22 JPMorgan
Adicet Bio initiated with an Overweight at JPMorgan
03/30/22 SMBC Nikko
Adicet Bio initiated with an Outperform at SMBC Nikko
03/17/22 JMP Securities
Adicet Bio price target lowered to $21 from $30 at JMP Securities
ACET Adicet Bio
$19.27 /

+0.135 (+0.71%)

  • 08
    Dec
ACET Adicet Bio
$19.27 /

+0.135 (+0.71%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.